Novotech CEO to speak on Clinical Projects – Faster and Smarter it’s All in the Planning at the 46th DIA Annual Meeting June 13-17 in Washington, DC

Washington, DC, June 13, 2010 – Leading Australian contract clinical research company Novotech announced today that Novotech CEO Alek Safarian will be sharing the company’s Asia Region expertise and experience at DIA 2010 to be held in Washington, DC.
Safarian will speak on “Global Study Experiences: Lessons from Observing Regional Variations” which is part of the [...]

Novotech embarks on a new strategic partnership with Citeline, designed to accelerate patient recruitment and complete clinical studies more quickly.

Novotech embarks on a new strategic partnership with Citeline, designed to accelerate patient recruitment and complete clinical studies more quickly.
NEW YORK – 15/4/10 – Novotech, a leading Australasian CRO, has engaged Citeline to support its clinical development programs and further improve the rate at which Sponsor clinical studies are planned and carried out.
Citeline, the leader [...]

Novotech announces four country Asia expansion at AusBiotech 2009

NOVOTECH ANNOUNCES FOUR COUNTRY ASIA EXPANSION AT AUSBIOTECH 2009
New operations in Malaysia, Singapore, Thailand, and Philippines
Sydney, Oct 27, 2009 – Leading Australian contract clinical research company Novotech announced today that it was expanding into four new Asian markets with the establishment of a management hub in Kuala Lumpur, Malaysia.
Novotech CEO Alek Safarian said the time [...]

New Study of Investigational Alzheimer’s Disease Treatment Enrolling Patients in Australia

New Study of Investigational Alzheimer’s Disease Treatment Enrolling Patients in Australia
Sydney, Australia – 31, August 2009 – It was announced today that a new global clinical trial has begun enrolling patients with Alzheimer’s disease in NSW, Victoria, Queensland, South Australia, and Western Australia.
The CONCERT study, is a new clinical trial that will test the efficacy [...]

Novotech wins coveted Australian CRO Award from Frost & Sullivan

San Diego, CA– June 19, 2008 — Novotech, the largest Australian owned contract
research organization (CRO) has confirmed its position as the pre-eminent Australian
based CRO with the award by leading industry analyst house Frost & Sullivan as the
Australian CRO of the Year. The award is part of the prestigious Excellence in
Healthcare Awards series covering a spectrum [...]

Athletes, and non-athletes, between 18 and 65 wanted for tinea study

ATHLETES’ FOOT AFFECTS MORE THAN 9% OF PEOPLE
Sydney, Australia – November 17, 2007 – A novel new oral treatment for Tinea, commonly known as Athletes’ Foot, is now being tested by Australian research teams in Melbourne, Sydney, Adelaide and Brisbane as part of a global study in the condition that affects over 9% [...]

Australian research teams test prawn shell treatment to combat hayfever

“DRUG FROM THE SEA” SHOWS POTENTIAL FOR ALLERGY SUFFERERS
Sydney, Australia – November 14, 2007 – A novel agent for the treatment of rhinitis, commonly known as hayfever, is now being tested by Australian research teams in Melbourne, Sydney, and Brisbane. The agent is derived from the shells of marine crustaceans.
Dr Rimmer from the Woolcock Institute [...]

Novotech in expansion mode as CRO sector continues to grow at 15%

BioPacificVentures and Co-Investor Capital Partners invest in Novotech and back expansion plans
Sydney, Australia, Orange County, CA – October 21, 2007 — Novotech, the largest Australian owned contract research organization (CRO) with offices on the US east and west coasts, is now in rapid expansion mode as the CRO sector fundamentals continue to strengthen with growth [...]

Novotech alerts Pharma and Biotechs at DIA 2007 to Australias new R&D tax break that applies to clinical trials

New Tax break comes into effect July 1, 2007
Atlanta, GA – July 1, 2007 — Novotech, the largest Australian owned contract research organization (CRO) with offices on the US east and west coasts, announced on the eve of DIA 2007 that the new tax breaks for research in Australia, which includes clinical trials, starts July [...]

Novotech says Australia ideally placed to become Bioequivalence trials hub

Sydney, Australia, May 15, 2007 — Novotech, the largest independent Australian owned contract research organization (CRO) with expertise in TGA/EMEA/FDA registration said today Australia should aggressively market its bioequivalence trials capabilities overseas and take a large share of the multi-billion dollar sector. Already more than 70% of Novotech’s bioequivalence work comes from offshore, according to [...]

Next Page »